Maternal outcomes after 12hours and 24hours of XXXX therapy for @entity3036 .

@entity1 @entity644 @entity410 @entity2399 @entity2400 @entity3036
OBJECTIVE: To assess the effectiveness of a reduced duration (12hours) of @entity2399 ( @entity2400 ) administration for @entity3036 . METHODS: In a prospective randomized study, @entity1 with @entity3036 (prepartum, intrapartum, or postpartum) attending Jawaharlal Nehru Medical College, Aligarh, India, between January 2012 and September 2013 were enrolled. The inclusion criteria were blood pressure of at least 140/90mm Hg after 20weeks, @entity644 (dipstick value>= +1), and @entity410 not attributed to other causes. @entity1 were assigned to control and study groups according to the time of enrollment (6-month blocks). All @entity1 received a @entity2400 loading dose (4g, intravenously), followed by maintenance doses (1g/hour) for 12hours (study group) and 24hours (control group). The primary outcome was recurrent @entity410 after completion of @entity2400 therapy. @entity1 with treatment failure were excluded from analyses. RESULTS: Analyses included 132 @entity1 in the study group and 72 @entity1 in the control group. No @entity410 recurred in either group after the completion of treatment. CONCLUSION: For @entity1 with @entity3036 , 12hours of @entity2399 could effectively prevent recurrent @entity410 .
